Supernus Pharmaceuticals (LTS:0LB2) Float Percentage Of Total Shares Outstanding: 81.41% (As of Jul. 01, 2026)


LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
88 GF Score
Price $46.89
GF Value $40.98
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Supernus Pharmaceuticals LTS:0LB2 +0.82% 88 Float Percentage Of Total Shares Outstanding is 81.41% as of Jul. 01, 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $40.98 (Modestly Overvalued).

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Supernus Pharmaceuticals's float shares is 47.25 Mil. Supernus Pharmaceuticals's total shares outstanding is 58.04 Mil. Supernus Pharmaceuticals's float percentage of total shares outstanding is 81.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Supernus Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Supernus Pharmaceuticals's Institutional Ownership is 63.35%.

LTS:0LB2
88GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Supernus Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=47.25/58.04
=81.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 81.41% mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Float Percentage Of Total Shares Outstanding of 81.41% as of Jul. 01, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Supernus Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 81.41%. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to BCRX and PBH?
Supernus Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 81.41% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 81.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.98, compared to a current price of $46.89 — trading 14.4% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 81.41%. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Float Percentage Of Total Shares Outstanding is 81.41% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $46.89 is trading 14.4% above its estimated GF Value™ of $40.98. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LTS:0LB2:

  • Float Percentage Of Total Shares Outstanding: 81.41%
  • GF Value™: $40.98 vs. price of $46.89 (14.4% above fair value)
  • GF Score™: 88/100

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score

Get the complete analysis for LTS:0LB2

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.89
Price
$40.98
GF Value